Sector News

GSK eyes $1.7B bid for respiratory partner Vectura: report

January 17, 2018
Life sciences

GlaxoSmithKline already partners with Vectura on respiratory therapies, but some say the British pharma giant could be looking to take the pair’s relationship one step further.

Glaxo is preparing a 175-pence-per-share bid for the Chippenham, U.K.-based company, sources told The Telegraph. That offer would value Vectura at close to £1.2 billion.

If GSK does strike, it’ll be taking advantage of Vectura’s 2017 share price drop. In May, the FDA turned down a generic of GlaxoSmithKline blockbuster Advair from Vectura and partner Hikma, and investors have continued to pressure the stock as they await a final verdict from the regulatory agency, due this quarter, the newspaper notes.

And last week’s investment strategy update didn’t sit particularly well with shareholders, either. In it, Vectura said it would increase its focus on lower-risk pipeline development opportunities and “cease” investment in “relatively higher risk, novel molecule, early stage programs,” instead looking for partnerships in that arena.

Glaxo knows what it would be getting itself into with a Vectura buy. The drugmaker licensed Vectura’s technology for products such as Breo and Anoro, and Vectura boasts some “smart inhaler” technology that GSK may be interested in, too, The Telegraph notes.

While CEO Emma Walmsley has made clear that reviving Glaxo’s pharma portfolio is a top priority,, right now all eyes are on the company’s consumer unit—at least when it comes to M&A. GSK is weighing a bid for Pfizer’s on-the-block OTC division, along with rivals including Reckitt Benckiser.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend